SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells $13,552.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00. Following the completion of the sale, the chief executive officer owned 3,726,150 shares of the company’s stock, valued at $18,034,566. This trade represents a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total transaction of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.77, for a total transaction of $21,398.22.

SOPHiA GENETICS Price Performance

NASDAQ SOPH opened at $4.70 on Monday. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The stock has a market capitalization of $321.90 million, a PE ratio of -9.22 and a beta of 1.04. The company has a 50 day moving average price of $4.75 and a two-hundred day moving average price of $4.70. SOPHiA GENETICS SA has a 12-month low of $2.58 and a 12-month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The business had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. As a group, equities analysts predict that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional accumulation — UBS, Akre and several other funds materially increased positions in recent quarters, signaling conviction from some large investors which could provide demand support for the stock.
• Positive Sentiment: Analyst upside — Guggenheim and BTIG have issued Buy ratings and target prices around $7, above the current trading level, giving the stock upside on positive research momentum.
• Neutral Sentiment: Multiple executives sold small blocks of shares under pre‑arranged Rule 10b5‑1 plans to cover tax withholding associated with vested awards; these are routine and reduce the informational signal from insider sales. Representative SEC filing for CEO sales. CEO Form 4
• Neutral Sentiment: Additional planned sales by other insiders (CFO, President, CTO and others) were disclosed; most trades are modest relative to executive holdings and were executed under 10b5‑1 plans — still worth monitoring for short‑term supply impact. Example coverage of a recent insider sale. InsiderTrades article
• Negative Sentiment: Short interest increased ~20% in late March to ~255k shares (≈0.4% of float), raising potential downward pressure and the possibility of elevated volatility if shorts add to positions or cover into thin trading days.
• Negative Sentiment: Recent fundamentals remain challenged — SOPH reported an EPS miss in early March and continues to show negative margins and ROE; analysts still model negative EPS for the year, which keeps valuation sensitivity high.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares during the period. Akre Capital Management LLC boosted its holdings in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after acquiring an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC bought a new stake in SOPHiA GENETICS during the third quarter valued at about $6,708,000. Royce & Associates LP bought a new stake in SOPHiA GENETICS during the fourth quarter valued at about $2,009,000. Finally, 1492 Capital Management LLC bought a new stake in SOPHiA GENETICS during the fourth quarter valued at about $973,000. 31.59% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SOPH has been the subject of a number of analyst reports. Guggenheim lifted their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. BTIG Research restated a “buy” rating and issued a $7.00 price objective on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.